The disease affects about 8,000 patients worldwide.TTR is a protein secreted by the liver and Pfizer's prospective drug destabilizes the proteins that form amyloid fibrils in the peripheral and autonomic nerves, as well as other organs including the gastrointestinal tract, kidneys and heart.Pfizer noted that the FDA expects to complete the fast-track review of the drug by June 2012.